Welcome to the Provis Infusion Clinic
The Provis Infusion Clinic is committed to the delivery of patient-focused services to assist physicians in the management of their patients.
At Provis Infusion Clinic we provide chemotherapy and other infusion services for treatments that are currently not covered under Ontario’s provincial health insurance plan thereby allowing physicians and their patients increased access to certain medications.
Our individualized service is delivered by highly trained professional staff in a non-institutional, friendly environment while operating under the highest standards and observing the Canada Health Act.
Patient safety is paramount to our service offering – we operate in a similar manner to a hospital chemotherapy unit. All infusions are performed by highly skilled oncology nurses, supervised by an on-site physician. All medication are compounded on-site, by pharmacy technicians, under a bio-hazard hood, supervised by oncology pharmacists.
Provis Infusion Clinic is a private Canadian corporation, not affiliated with any other organization or institution.
We look forward to being of service to you.
Graham Vincent, President
The Provis Infusion Clinic
Welcome to the new Provis WebsiteWe are pleased to offer this new website for your information and use. Please copy or click www.provisinfusion.com and update your web browser. .
Why Choose Provis?
- Infusion Services Since 2005
- Over 8000+ Infusions To Date
- Most Comprehensive Oncology Drug Formulary in Canada
- Onsite Medication Compounding Facility
- Experienced Pharmacists On-Site
- Experienced Oncology Trained Nurses
- Supervising Physician On-Site
10 Year Anniversary!The Provis Infusion Clinic is please to announce that August 2015 marks the 10 anniversary of the Provis Infusion Clinic. We are looking forward to the next 10 years of providing high quality infusion services.
Opdivo™ (Nivolumab) receives Health Canada approval.Opdivo™ is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made under the Health Canada Priority Review process, after having met the criteria of substantial evidence of clinical effectiveness providing an improved benefit/risk profile over existing therapies. Provis is also able to provide Opdivo™ for other indications if required.
Keytruda™ (Pembrolizumab) now offered at ProvisAUTHORIZATION WITH CONDITIONS OF KEYTRUDA™ for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor
The Ride to Conquer CancerThe Provis Pelotons Cycling Team participate in the 2015 Ride to Conquer Cancer. The ride is over 220km's from Toronto to Niagara Falls. The team raised close to $13,000 for cancer research. Way to go Graham, Deb, Steve, Samantha and Dave.
Update – Patient Support Programs
Keytruda®, Perjeta®, Herceptin®, Avastin®,Jevtana®, Rituxan®, Abraxane®, Treanda® and Kadcyla® Patients: Provis participates in the Roche Patient Assistance Program, the Treanda Support Program, the Merck Care Oncology and Celgene Abraxane® Access Program . These program offers financial assistance to qualified patients receiving Keytruda® Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®,Treanda® and Kadcyla® Read More >>
Non-Muscle Invasive Bladder CancerProvis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.
New Combined-Therapy Option For Metastatic Pancreatic CancerCombined Abraxane (nab-paclitaxel) plus gemcitabine provides superior efficacy vs. gemcitabine alone for metastatic pancreatic cancer